The drug is a prodrug and is activated in the acidic environment of the secretory tubules in the parietal cells. It reduces basal and stimulated secretion regardless of the nature of the stimulus. Prescribed in case of erosive ulcerative diseases of the gastrointestinal tract and eradication of Helicobacter pylori in infected patients with gastric and duodenal ulcer.

Pharmacological influence of Calan is explained by braking of a flow of calcium ions through the slowed-down calcic tubules of cellular covers of smooth muscle structure of vessels and a cardiac muscle. Calan is prescribed if it was diagnosed paroxysmal supraventricular tachycardia (except WPW syndrome), sinus tachycardia, premature atrial contraction, blinking and atrial flutter, stenocardia (inc. stress, postinfarction), arterial hypertension, hypertensive crisis, idiopathic hypertrophic subaortic stenosis, hypertrophic cardiomyopathy.